Protalix BioTherapeutics Reports First Quarter 2026 Financial Results and Reaffirms Guidance

Protalix BioTherapeutics, Inc.

• Received $25 million milestone from Chiesi following European Commission approval of Elfabrio 2 mg/kg every-4-weeks dosing regimen.
• PRX-115 Phase 2 RELEASE study for uncontrolled gout continues; top-line results expected second half of 2027.
• Reaffirms 2026 revenue guidance of $78.0-$83.0 million including $25 million milestone; Elfabrio sales $33-$35 million, Elelyso $20-$23 million.
• Cash and equivalents $51 million as of March 31, 2026; no outstanding debt or warrants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.